Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $92.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price target lowered by equities research analysts at Robert W. Baird from $96.00 to $92.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 199.19% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. HC Wainwright dropped their target price on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. UBS Group dropped their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. JPMorgan Chase & Co. reduced their target price on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. The Goldman Sachs Group boosted their price target on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $70.20.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock opened at $30.75 on Monday. Apellis Pharmaceuticals has a 52 week low of $30.74 and a 52 week high of $73.80. The firm has a market cap of $3.73 billion, a P/E ratio of -8.89 and a beta of 0.88. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. The business’s fifty day moving average is $37.52 and its two-hundred day moving average is $43.10.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. During the same quarter in the prior year, the firm earned ($1.02) EPS. The company’s revenue was up 110.2% on a year-over-year basis. Equities research analysts forecast that Apellis Pharmaceuticals will post -1.29 earnings per share for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at $3,623,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 6.80% of the stock is owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Norges Bank bought a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth $56,640,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth about $3,218,000. Bellevue Group AG grew its holdings in shares of Apellis Pharmaceuticals by 3.5% in the 4th quarter. Bellevue Group AG now owns 821,800 shares of the company’s stock valued at $49,193,000 after acquiring an additional 27,959 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Apellis Pharmaceuticals in the first quarter valued at about $942,000. Finally, Altitude Crest Partners Inc. bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth about $9,111,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).